Clinical TrialJun 30, 2026, 07:01 AM
AC Immune Reports Interim ACI-24 Phase 1b/2 AD Trial Data
AI Summary
AC Immune SA announced positive interim 12-month data from the first three cohorts (AD1-3) of its Phase 1b/2 ABATE trial for ACI-24 in 74 patients with prodromal Alzheimer’s disease. The anti-Abeta active immunotherapy was generally safe and well tolerated, showing no evidence of ARIA-E and demonstrating anti-Abeta antibody dose-response. The company has initiated an AD4 cohort to evaluate ACI-24 with an additional adjuvant to further enhance immunogenicity, triggering a $12 million milestone payment from Takeda, in addition to the $100 million upfront payment already received.
Key Highlights
- Interim 12-month data from Phase 1b/2 ABATE trial of ACI-24 in prodromal AD.
- ACI-24 was generally safe and well tolerated in 74 patients across AD1-3 cohorts.
- No evidence of amyloid-related imaging abnormalities-edema (ARIA-E) observed.
- Anti-Abeta antibody dose-response detected at all dose levels in AD1-3 cohorts.
- AD4 cohort initiated to evaluate ACI-24 with an additional adjuvant for enhanced immunogenicity.
- Received $100 million upfront payment and $12 million milestone from Takeda.
- Eligible for up to $2.1 billion in additional potential milestones from Takeda.
Price Impact
More from ACIU